# A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus

> **NCT01031108** · PHASE1 · COMPLETED · sponsor: **Sirtris, a GSK Company** · enrollment: 38 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** SRT2104

## Key facts

- **NCT ID:** NCT01031108
- **Lead sponsor:** Sirtris, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-28
- **Primary completion:** 2011-10-12
- **Final completion:** 2011-10-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031108, "A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01031108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*